1. Home
  2. ESQ vs DBVT Comparison

ESQ vs DBVT Comparison

Compare ESQ & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$122.14

Market Cap

941.0M

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$13.68

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESQ
DBVT
Founded
2006
2002
Country
United States
France
Employees
N/A
90
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.0M
948.8M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
ESQ
DBVT
Price
$122.14
$13.68
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$120.33
$32.04
AVG Volume (30 Days)
136.3K
275.2K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
0.76%
N/A
EPS Growth
14.20
10.26
EPS
1.40
N/A
Revenue
N/A
$5,636,000.00
Revenue This Year
$35.15
$35.04
Revenue Next Year
$39.09
$2,360.78
P/E Ratio
$82.87
N/A
Revenue Growth
N/A
35.77
52 Week Low
$90.57
$8.51
52 Week High
$125.85
$26.19

Technical Indicators

Market Signals
Indicator
ESQ
DBVT
Relative Strength Index (RSI) 56.34 32.26
Support Level $103.79 $12.63
Resistance Level $125.40 $14.68
Average True Range (ATR) 3.42 0.87
MACD -0.36 -0.17
Stochastic Oscillator 69.41 11.88

Price Performance

Historical Comparison
ESQ
DBVT

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: